IceCure Medical (ICCM) announced it has received a notification letter from Nasdaq Stock Market confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). IceCure is now in full compliance with all Nasdaq continued listing requirements and will continue to be listed and traded on The Nasdaq Capital Market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical Secures European Patent for Next-Generation Cryoablation Technology
- IceCure Medical receives Intention to Grant notice from EPO
- Icecure Medical Appoints New Board Director with Financial Expertise
- IceCure Medical’s Cryoablation Success in Kidney Tumors
- IceCure Medical’s ProSense cryoablation shows efficacy in kidney tumor study
Questions or Comments about the article? Write to editor@tipranks.com